Watch Our Webinar on How to Elevate Gene Editing With Cas-CLOVER
This recorded webinar covers the topic on “Cas-CLOVER: A Clean Alternative to CRISPR” hosted by GEN: Genetic Engineering and Biotechnology News.
As a quick recap, Cas-CLOVER is a novel gene editing technology, which differs from traditional single-guided Cas9 and dual-guided Cas9-nickase methods. This dimeric system has undetectable off-target activity and stand alone patent protection for licensing simplicity and clarity in freedom to operate.
Validated In CHO Cells, Yeast, Plants & Human T-Cells
In our webinar, two experts presented data on Cas-CLOVER fundamentals such as architecture, design and implementation in cells, yeast, plants as well as advanced gene editing in human T-cells for allogeneic CAR-T therapies.
To learn more about the area you are interested in, download the relevant industry datasheet.
Therapeutic Bioprocessing
Clean & clear CHO cell editing and GS CHO knockouts for bioprocessing
Agriculture Biotechnology
Advanced crop trait engineering, the non-GMO way
Synthetic Biotechnology
Harnessing the power of targeted yeast editing
Watch The Recorded Webinars
Enhance your gene editing research or commercial interests with Cas-CLOVER. The recorded webinars hosted by Genetic Engineering & Biotechnology News are available below so that you can watch the areas that apply to your research.
Tseten Jamling, PhD.
Vice President,
R&D and Gene Editing
Hera BioLabs
Cas-CLOVER fundamentals, immunotherapy model creation, CHO cell editing, yeast, & plant trait development.
Maximilian Richter, PhD.
Senior Scientist,
Immuno-Oncology
Poseida Therapeutics
Advanced T-cell engineering to overcome known challenges with autologous CAR-T.
What’s Unique About The Cas-CLOVER Gene Editing System?
As opposed to the use of a single guide RNA (gRNA) for sequence-specific gene editing, the Cas-CLOVER system utilizes a dual gRNA in addition to the Clo51 nuclease activity that requires dimerization of subunits associated with each guide RNA.
This allows for more stringent DNA cleavage. Using two gRNA makes the Cas-CLOVER gene editing system highly restricted and only functional when the paired gRNAs coexist.
Freedom To Operate Is Clear With Cas-CLOVER
The lack of clear commercial freedom to operate and use of intellectual property (IP) has limited the commercial use of current gene editing tools. It is our mission to make technology easily accessible to all scientists and researchers within the pharmaceutical bioprocessing, industrial biotechnology, and agriculture industries.
Due to the distinct science involved, Cas-CLOVER is covered under a set of patents separate from other technologies. Cas-CLOVER is exclusively licensed and sub-licensable by Demeetra.
Scientists Trust Cas-CLOVER
Evaluate Cas-CLOVER in-house or collaborate with us to execute your proof of concept services. Then, partner with us for accessible commercial and research sub licenses for the areas of agriculture, industrial biotechnology, pharmaceutical bioprocessing and drug discovery/development for a more rewarding gene editing experience.
Explore Your Options with Novel
Gene Editing Technology
Request reagents or information on licensing and services to get started.
HERA BIOLABS
2277 THUNDERSTICK DR. #500 LEXINGTON, KY 40505 US
COPYRIGHT © 2020 HERA BIOLABS. – ALL RIGHTS RESERVED.